APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cholesterol Lowering Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Cholesterol Lowering Drugs Industry Research Report 2026

Report ID 173977730528 December 2025143 pages

Choose your research edition.

Industry ResearchCholesterol Lowering Drugs Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Cholesterol Lowering Drugs Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Cholesterol Lowering Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cholesterol Lowering Drugs Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Cholesterol Lowering Drugs Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Cholesterol Lowering Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Cholesterol Lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Cholesterol Lowering Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Cholesterol Lowering Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Cholesterol Lowering Drugs include Innovent Biologics, Sanofi, Novartis, Merck, Akeso, Pfizer, Hisun Pharmaceutical, Zydus and Viatris, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Cholesterol Lowering Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Cholesterol Lowering Drugs Market by Company

Innovent Biologics

Sanofi

Novartis

Merck

Akeso

Pfizer

Hisun Pharmaceutical

Zydus

Viatris

Teva

Regeneron Pharmaceuticals

Otsuka Pharmaceutical

Medicure Pharma

Kowa Pharmaceuticals

Glenmark

Esperion Therapeutics

Cosette Pharmaceuticals

Cheplapharm Arzneimittel

Apotex

Amgen

Cholesterol Lowering Drugs Segment by Type

PCSK9 Inhibitors

Cholesterol Chelators

Cholesterol Absorption Inhibitors

Statins

Others

Cholesterol Lowering Drugs Segment by Application

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Cholesterol Lowering Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cholesterol Lowering Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cholesterol Lowering Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cholesterol Lowering Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Cholesterol Lowering Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Cholesterol Lowering Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Cholesterol Lowering Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Cholesterol Lowering Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Cholesterol Lowering Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Cholesterol Lowering Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Cholesterol Lowering Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Cholesterol Lowering Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Cholesterol Lowering Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Cholesterol Lowering Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Cholesterol Lowering Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Cholesterol Lowering Drugs, Product Type & Application Table 14. Global Cholesterol Lowering Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Cholesterol Lowering Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Innovent Biologics Company Information Table 19. Innovent Biologics Business Overview Table 20. Innovent Biologics Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Innovent Biologics Cholesterol Lowering Drugs Product Portfolio Table 22. Innovent Biologics Recent Developments Table 23. Sanofi Company Information Table 24. Sanofi Business Overview Table 25. Sanofi Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Sanofi Cholesterol Lowering Drugs Product Portfolio Table 27. Sanofi Recent Developments Table 28. Novartis Company Information Table 29. Novartis Business Overview Table 30. Novartis Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Novartis Cholesterol Lowering Drugs Product Portfolio Table 32. Novartis Recent Developments Table 33. Merck Company Information Table 34. Merck Business Overview Table 35. Merck Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Merck Cholesterol Lowering Drugs Product Portfolio Table 37. Merck Recent Developments Table 38. Akeso Company Information Table 39. Akeso Business Overview Table 40. Akeso Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Akeso Cholesterol Lowering Drugs Product Portfolio Table 42. Akeso Recent Developments Table 43. Pfizer Company Information Table 44. Pfizer Business Overview Table 45. Pfizer Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Pfizer Cholesterol Lowering Drugs Product Portfolio Table 47. Pfizer Recent Developments Table 48. Hisun Pharmaceutical Company Information Table 49. Hisun Pharmaceutical Business Overview Table 50. Hisun Pharmaceutical Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Hisun Pharmaceutical Cholesterol Lowering Drugs Product Portfolio Table 52. Hisun Pharmaceutical Recent Developments Table 53. Zydus Company Information Table 54. Zydus Business Overview Table 55. Zydus Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Zydus Cholesterol Lowering Drugs Product Portfolio Table 57. Zydus Recent Developments Table 58. Viatris Company Information Table 59. Viatris Business Overview Table 60. Viatris Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Viatris Cholesterol Lowering Drugs Product Portfolio Table 62. Viatris Recent Developments Table 63. Teva Company Information Table 64. Teva Business Overview Table 65. Teva Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Teva Cholesterol Lowering Drugs Product Portfolio Table 67. Teva Recent Developments Table 68. Regeneron Pharmaceuticals Company Information Table 69. Regeneron Pharmaceuticals Business Overview Table 70. Regeneron Pharmaceuticals Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Regeneron Pharmaceuticals Cholesterol Lowering Drugs Product Portfolio Table 72. Regeneron Pharmaceuticals Recent Developments Table 73. Otsuka Pharmaceutical Company Information Table 74. Otsuka Pharmaceutical Business Overview Table 75. Otsuka Pharmaceutical Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Otsuka Pharmaceutical Cholesterol Lowering Drugs Product Portfolio Table 77. Otsuka Pharmaceutical Recent Developments Table 78. Medicure Pharma Company Information Table 79. Medicure Pharma Business Overview Table 80. Medicure Pharma Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Medicure Pharma Cholesterol Lowering Drugs Product Portfolio Table 82. Medicure Pharma Recent Developments Table 83. Kowa Pharmaceuticals Company Information Table 84. Kowa Pharmaceuticals Business Overview Table 85. Kowa Pharmaceuticals Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Kowa Pharmaceuticals Cholesterol Lowering Drugs Product Portfolio Table 87. Kowa Pharmaceuticals Recent Developments Table 88. Glenmark Company Information Table 89. Glenmark Business Overview Table 90. Glenmark Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Glenmark Cholesterol Lowering Drugs Product Portfolio Table 92. Glenmark Recent Developments Table 93. Esperion Therapeutics Company Information Table 94. Esperion Therapeutics Business Overview Table 95. Esperion Therapeutics Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Esperion Therapeutics Cholesterol Lowering Drugs Product Portfolio Table 97. Esperion Therapeutics Recent Developments Table 98. Cosette Pharmaceuticals Company Information Table 99. Cosette Pharmaceuticals Business Overview Table 100. Cosette Pharmaceuticals Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Cosette Pharmaceuticals Cholesterol Lowering Drugs Product Portfolio Table 102. Cosette Pharmaceuticals Recent Developments Table 103. Cheplapharm Arzneimittel Company Information Table 104. Cheplapharm Arzneimittel Business Overview Table 105. Cheplapharm Arzneimittel Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Cheplapharm Arzneimittel Cholesterol Lowering Drugs Product Portfolio Table 107. Cheplapharm Arzneimittel Recent Developments Table 108. Apotex Company Information Table 109. Apotex Business Overview Table 110. Apotex Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Apotex Cholesterol Lowering Drugs Product Portfolio Table 112. Apotex Recent Developments Table 113. Amgen Company Information Table 114. Amgen Business Overview Table 115. Amgen Cholesterol Lowering Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Amgen Cholesterol Lowering Drugs Product Portfolio Table 117. Amgen Recent Developments Table 118. Global Cholesterol Lowering Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 119. Global Cholesterol Lowering Drugs Sales by Region (2021-2026) & (K Units) Table 120. Global Cholesterol Lowering Drugs Sales Market Share by Region (2021-2026) Table 121. Global Cholesterol Lowering Drugs Sales by Region (2027-2032) & (K Units) Table 122. Global Cholesterol Lowering Drugs Sales Market Share by Region (2027-2032) Table 123. Global Cholesterol Lowering Drugs Revenue by Region (2021-2026) & (US$ Million) Table 124. Global Cholesterol Lowering Drugs Revenue Market Share by Region (2021-2026) Table 125. Global Cholesterol Lowering Drugs Revenue by Region (2027-2032) & (US$ Million) Table 126. Global Cholesterol Lowering Drugs Revenue Market Share by Region (2027-2032) Table 127. North America Cholesterol Lowering Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. North America Cholesterol Lowering Drugs Sales by Country (2021-2026) & (K Units) Table 129. North America Cholesterol Lowering Drugs Sales by Country (2027-2032) & (K Units) Table 130. North America Cholesterol Lowering Drugs Revenue by Country (2021-2026) & (US$ Million) Table 131. North America Cholesterol Lowering Drugs Revenue by Country (2027-2032) & (US$ Million) Table 132. Europe Cholesterol Lowering Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Europe Cholesterol Lowering Drugs Sales by Country (2021-2026) & (K Units) Table 134. Europe Cholesterol Lowering Drugs Sales by Country (2027-2032) & (K Units) Table 135. Europe Cholesterol Lowering Drugs Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe Cholesterol Lowering Drugs Revenue by Country (2027-2032) & (US$ Million) Table 137. Asia Pacific Cholesterol Lowering Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Asia Pacific Cholesterol Lowering Drugs Sales by Country (2021-2026) & (K Units) Table 139. Asia Pacific Cholesterol Lowering Drugs Sales by Country (2027-2032) & (K Units) Table 140. Asia Pacific Cholesterol Lowering Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. Asia Pacific Cholesterol Lowering Drugs Revenue by Country (2027-2032) & (US$ Million) Table 142. South America Cholesterol Lowering Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. South America Cholesterol Lowering Drugs Sales by Country (2021-2026) & (K Units) Table 144. South America Cholesterol Lowering Drugs Sales by Country (2027-2032) & (K Units) Table 145. South America Cholesterol Lowering Drugs Revenue by Country (2021-2026) & (US$ Million) Table 146. South America Cholesterol Lowering Drugs Revenue by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa Cholesterol Lowering Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Middle East and Africa Cholesterol Lowering Drugs Sales by Country (2021-2026) & (K Units) Table 149. Middle East and Africa Cholesterol Lowering Drugs Sales by Country (2027-2032) & (K Units) Table 150. Middle East and Africa Cholesterol Lowering Drugs Revenue by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa Cholesterol Lowering Drugs Revenue by Country (2027-2032) & (US$ Million) Table 152. Global Cholesterol Lowering Drugs Sales by Type (2021-2026) & (K Units) Table 153. Global Cholesterol Lowering Drugs Sales by Type (2027-2032) & (K Units) Table 154. Global Cholesterol Lowering Drugs Sales Market Share by Type (2021-2026) Table 155. Global Cholesterol Lowering Drugs Sales Market Share by Type (2027-2032) Table 156. Global Cholesterol Lowering Drugs Revenue by Type (2021-2026) & (US$ Million) Table 157. Global Cholesterol Lowering Drugs Revenue by Type (2027-2032) & (US$ Million) Table 158. Global Cholesterol Lowering Drugs Revenue Market Share by Type (2021-2026) Table 159. Global Cholesterol Lowering Drugs Revenue Market Share by Type (2027-2032) Table 160. Global Cholesterol Lowering Drugs Price by Type (2021-2026) & (US$/Unit) Table 161. Global Cholesterol Lowering Drugs Price by Type (2027-2032) & (US$/Unit) Table 162. Global Cholesterol Lowering Drugs Sales by Application (2021-2026) & (K Units) Table 163. Global Cholesterol Lowering Drugs Sales by Application (2027-2032) & (K Units) Table 164. Global Cholesterol Lowering Drugs Sales Market Share by Application (2021-2026) Table 165. Global Cholesterol Lowering Drugs Sales Market Share by Application (2027-2032) Table 166. Global Cholesterol Lowering Drugs Revenue by Application (2021-2026) & (US$ Million) Table 167. Global Cholesterol Lowering Drugs Revenue by Application (2027-2032) & (US$ Million) Table 168. Global Cholesterol Lowering Drugs Revenue Market Share by Application (2021-2026) Table 169. Global Cholesterol Lowering Drugs Revenue Market Share by Application (2027-2032) Table 170. Global Cholesterol Lowering Drugs Price by Application (2021-2026) & (US$/Unit) Table 171. Global Cholesterol Lowering Drugs Price by Application (2027-2032) & (US$/Unit) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Cholesterol Lowering Drugs Distributors List Table 175. Cholesterol Lowering Drugs Customers List Table 176. Cholesterol Lowering Drugs Industry Trends Table 177. Cholesterol Lowering Drugs Industry Drivers Table 178. Cholesterol Lowering Drugs Industry Restraints Table 179. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Cholesterol Lowering Drugs Product Image Figure 5. Global Cholesterol Lowering Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Cholesterol Lowering Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Cholesterol Lowering Drugs Sales (2021-2032) & (K Units) Figure 8. Global Cholesterol Lowering Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. PCSK9 Inhibitors Product Image Figure 10. Cholesterol Chelators Product Image Figure 11. Cholesterol Absorption Inhibitors Product Image Figure 12. Statins Product Image Figure 13. Others Product Image Figure 14. Hospital Pharmacy Product Image Figure 15. Retail Pharmacy Product Image Figure 16. Online Pharmacy Product Image Figure 17. Global Cholesterol Lowering Drugs Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Cholesterol Lowering Drugs, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Cholesterol Lowering Drugs Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Cholesterol Lowering Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Cholesterol Lowering Drugs Sales by Region in 2025 Figure 23. Global Cholesterol Lowering Drugs Revenue by Region in 2025 Figure 24. North America Cholesterol Lowering Drugs Market Size by Country in 2025 Figure 25. North America Cholesterol Lowering Drugs Sales Market Share by Country (2021-2032) Figure 26. North America Cholesterol Lowering Drugs Revenue Market Share by Country (2021-2032) Figure 27. United States Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Cholesterol Lowering Drugs Market Size by Country in 2025 Figure 31. Europe Cholesterol Lowering Drugs Sales Market Share by Country (2021-2032) Figure 32. Europe Cholesterol Lowering Drugs Revenue Market Share by Country (2021-2032) Figure 33. Germany Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Cholesterol Lowering Drugs Market Size by Country in 2025 Figure 44. Asia Pacific Cholesterol Lowering Drugs Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Cholesterol Lowering Drugs Revenue Market Share by Country (2021-2032) Figure 46. China Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Cholesterol Lowering Drugs Market Size by Country in 2025 Figure 55. South America Cholesterol Lowering Drugs Sales Market Share by Country (2021-2032) Figure 56. South America Cholesterol Lowering Drugs Revenue Market Share by Country (2021-2032) Figure 57. Brazil Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Colombia Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Cholesterol Lowering Drugs Market Size by Country in 2025 Figure 62. Middle East and Africa Cholesterol Lowering Drugs Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Cholesterol Lowering Drugs Revenue Market Share by Country (2021-2032) Figure 64. Egypt Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Cholesterol Lowering Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Cholesterol Lowering Drugs Sales Market Share by Type (2021-2032) Figure 70. Global Cholesterol Lowering Drugs Revenue Market Share by Type (2021-2032) Figure 71. Global Cholesterol Lowering Drugs Price (US$/Unit) by Type (2021-2032) Figure 72. Global Cholesterol Lowering Drugs Sales Market Share by Application (2021-2032) Figure 73. Global Cholesterol Lowering Drugs Revenue Market Share by Application (2021-2032) Figure 74. Global Cholesterol Lowering Drugs Price (US$/Unit) by Application (2021-2032) Figure 75. Cholesterol Lowering Drugs Value Chain Figure 76. Cholesterol Lowering Drugs Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Cholesterol Lowering Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • PCSK9 Inhibitors
  • Cholesterol Chelators
  • Cholesterol Absorption Inhibitors
  • Statins
  • Others
Applications
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Companies covered
  • Innovent Biologics
  • Sanofi
  • Novartis
  • Merck
  • Akeso
  • Pfizer
  • Hisun Pharmaceutical
  • Zydus
  • Viatris
  • Teva
  • Regeneron Pharmaceuticals
  • Otsuka Pharmaceutical
  • Medicure Pharma
  • Kowa Pharmaceuticals
  • Glenmark
  • Esperion Therapeutics
  • Cosette Pharmaceuticals
  • Cheplapharm Arzneimittel
  • Apotex
  • Amgen

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Cholesterol Lowering Drugs Market Size (2021-2032)
  4. 2.2.2 Global Cholesterol Lowering Drugs Sales (2021-2032)
  5. 2.2.3 Global Cholesterol Lowering Drugs Market Average Price (2021-2032)
  6. 2.3 Cholesterol Lowering Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 PCSK9 Inhibitors
  9. 2.3.3 Cholesterol Chelators
  10. 2.3.4 Cholesterol Absorption Inhibitors
  11. 2.3.5 Statins
  12. 2.3.6 Others
  13. 2.4 Cholesterol Lowering Drugs by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Hospital Pharmacy
  16. 2.4.3 Retail Pharmacy
  17. 2.4.4 Online Pharmacy
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Cholesterol Lowering Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Cholesterol Lowering Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Cholesterol Lowering Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Cholesterol Lowering Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Cholesterol Lowering Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Cholesterol Lowering Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Cholesterol Lowering Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Cholesterol Lowering Drugs, Established Date
  9. 3.9 Global Cholesterol Lowering Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Innovent Biologics
  2. 4.1.1 Innovent Biologics Company Information
  3. 4.1.2 Innovent Biologics Business Overview
  4. 4.1.3 Innovent Biologics Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Innovent Biologics Cholesterol Lowering Drugs Product Portfolio
  6. 4.1.5 Innovent Biologics Recent Developments
  7. 4.2 Sanofi
  8. 4.2.1 Sanofi Company Information
  9. 4.2.2 Sanofi Business Overview
  10. 4.2.3 Sanofi Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi Cholesterol Lowering Drugs Product Portfolio
  12. 4.2.5 Sanofi Recent Developments
  13. 4.3 Novartis
  14. 4.3.1 Novartis Company Information
  15. 4.3.2 Novartis Business Overview
  16. 4.3.3 Novartis Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis Cholesterol Lowering Drugs Product Portfolio
  18. 4.3.5 Novartis Recent Developments
  19. 4.4 Merck
  20. 4.4.1 Merck Company Information
  21. 4.4.2 Merck Business Overview
  22. 4.4.3 Merck Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Merck Cholesterol Lowering Drugs Product Portfolio
  24. 4.4.5 Merck Recent Developments
  25. 4.5 Akeso
  26. 4.5.1 Akeso Company Information
  27. 4.5.2 Akeso Business Overview
  28. 4.5.3 Akeso Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Akeso Cholesterol Lowering Drugs Product Portfolio
  30. 4.5.5 Akeso Recent Developments
  31. 4.6 Pfizer
  32. 4.6.1 Pfizer Company Information
  33. 4.6.2 Pfizer Business Overview
  34. 4.6.3 Pfizer Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Pfizer Cholesterol Lowering Drugs Product Portfolio
  36. 4.6.5 Pfizer Recent Developments
  37. 4.7 Hisun Pharmaceutical
  38. 4.7.1 Hisun Pharmaceutical Company Information
  39. 4.7.2 Hisun Pharmaceutical Business Overview
  40. 4.7.3 Hisun Pharmaceutical Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Hisun Pharmaceutical Cholesterol Lowering Drugs Product Portfolio
  42. 4.7.5 Hisun Pharmaceutical Recent Developments
  43. 4.8 Zydus
  44. 4.8.1 Zydus Company Information
  45. 4.8.2 Zydus Business Overview
  46. 4.8.3 Zydus Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Zydus Cholesterol Lowering Drugs Product Portfolio
  48. 4.8.5 Zydus Recent Developments
  49. 4.9 Viatris
  50. 4.9.1 Viatris Company Information
  51. 4.9.2 Viatris Business Overview
  52. 4.9.3 Viatris Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Viatris Cholesterol Lowering Drugs Product Portfolio
  54. 4.9.5 Viatris Recent Developments
  55. 4.10 Teva
  56. 4.10.1 Teva Company Information
  57. 4.10.2 Teva Business Overview
  58. 4.10.3 Teva Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Teva Cholesterol Lowering Drugs Product Portfolio
  60. 4.10.5 Teva Recent Developments
  61. 4.11 Regeneron Pharmaceuticals
  62. 4.11.1 Regeneron Pharmaceuticals Company Information
  63. 4.11.2 Regeneron Pharmaceuticals Business Overview
  64. 4.11.3 Regeneron Pharmaceuticals Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Regeneron Pharmaceuticals Cholesterol Lowering Drugs Product Portfolio
  66. 4.11.5 Regeneron Pharmaceuticals Recent Developments
  67. 4.12 Otsuka Pharmaceutical
  68. 4.12.1 Otsuka Pharmaceutical Company Information
  69. 4.12.2 Otsuka Pharmaceutical Business Overview
  70. 4.12.3 Otsuka Pharmaceutical Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Otsuka Pharmaceutical Cholesterol Lowering Drugs Product Portfolio
  72. 4.12.5 Otsuka Pharmaceutical Recent Developments
  73. 4.13 Medicure Pharma
  74. 4.13.1 Medicure Pharma Company Information
  75. 4.13.2 Medicure Pharma Business Overview
  76. 4.13.3 Medicure Pharma Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Medicure Pharma Cholesterol Lowering Drugs Product Portfolio
  78. 4.13.5 Medicure Pharma Recent Developments
  79. 4.14 Kowa Pharmaceuticals
  80. 4.14.1 Kowa Pharmaceuticals Company Information
  81. 4.14.2 Kowa Pharmaceuticals Business Overview
  82. 4.14.3 Kowa Pharmaceuticals Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Kowa Pharmaceuticals Cholesterol Lowering Drugs Product Portfolio
  84. 4.14.5 Kowa Pharmaceuticals Recent Developments
  85. 4.15 Glenmark
  86. 4.15.1 Glenmark Company Information
  87. 4.15.2 Glenmark Business Overview
  88. 4.15.3 Glenmark Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Glenmark Cholesterol Lowering Drugs Product Portfolio
  90. 4.15.5 Glenmark Recent Developments
  91. 4.16 Esperion Therapeutics
  92. 4.16.1 Esperion Therapeutics Company Information
  93. 4.16.2 Esperion Therapeutics Business Overview
  94. 4.16.3 Esperion Therapeutics Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Esperion Therapeutics Cholesterol Lowering Drugs Product Portfolio
  96. 4.16.5 Esperion Therapeutics Recent Developments
  97. 4.17 Cosette Pharmaceuticals
  98. 4.17.1 Cosette Pharmaceuticals Company Information
  99. 4.17.2 Cosette Pharmaceuticals Business Overview
  100. 4.17.3 Cosette Pharmaceuticals Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Cosette Pharmaceuticals Cholesterol Lowering Drugs Product Portfolio
  102. 4.17.5 Cosette Pharmaceuticals Recent Developments
  103. 4.18 Cheplapharm Arzneimittel
  104. 4.18.1 Cheplapharm Arzneimittel Company Information
  105. 4.18.2 Cheplapharm Arzneimittel Business Overview
  106. 4.18.3 Cheplapharm Arzneimittel Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Cheplapharm Arzneimittel Cholesterol Lowering Drugs Product Portfolio
  108. 4.18.5 Cheplapharm Arzneimittel Recent Developments
  109. 4.19 Apotex
  110. 4.19.1 Apotex Company Information
  111. 4.19.2 Apotex Business Overview
  112. 4.19.3 Apotex Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Apotex Cholesterol Lowering Drugs Product Portfolio
  114. 4.19.5 Apotex Recent Developments
  115. 4.20 Amgen
  116. 4.20.1 Amgen Company Information
  117. 4.20.2 Amgen Business Overview
  118. 4.20.3 Amgen Cholesterol Lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Amgen Cholesterol Lowering Drugs Product Portfolio
  120. 4.20.5 Amgen Recent Developments
5 Global Cholesterol Lowering Drugs Market Scenario by Region
  1. 5.1 Global Cholesterol Lowering Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Cholesterol Lowering Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Cholesterol Lowering Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Cholesterol Lowering Drugs Sales by Region: 2027-2032
  5. 5.3 Global Cholesterol Lowering Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Cholesterol Lowering Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Cholesterol Lowering Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Cholesterol Lowering Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Cholesterol Lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Cholesterol Lowering Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Cholesterol Lowering Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Cholesterol Lowering Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Cholesterol Lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Cholesterol Lowering Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Cholesterol Lowering Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Cholesterol Lowering Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Cholesterol Lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Cholesterol Lowering Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Cholesterol Lowering Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Cholesterol Lowering Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Cholesterol Lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Cholesterol Lowering Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Cholesterol Lowering Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Cholesterol Lowering Drugs Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Cholesterol Lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Cholesterol Lowering Drugs Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Cholesterol Lowering Drugs Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Cholesterol Lowering Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Cholesterol Lowering Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Cholesterol Lowering Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Cholesterol Lowering Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Cholesterol Lowering Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Cholesterol Lowering Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Cholesterol Lowering Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Cholesterol Lowering Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Cholesterol Lowering Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Cholesterol Lowering Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Cholesterol Lowering Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Cholesterol Lowering Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Cholesterol Lowering Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Cholesterol Lowering Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Cholesterol Lowering Drugs Value Chain Analysis
  2. 8.1.1 Cholesterol Lowering Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Cholesterol Lowering Drugs Production Mode & Process
  5. 8.2 Cholesterol Lowering Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Cholesterol Lowering Drugs Distributors
  8. 8.2.3 Cholesterol Lowering Drugs Customers
9 Global Cholesterol Lowering Drugs Analyzing Market Dynamics
  1. 9.1 Cholesterol Lowering Drugs Industry Trends
  2. 9.2 Cholesterol Lowering Drugs Industry Drivers
  3. 9.3 Cholesterol Lowering Drugs Industry Opportunities and Challenges
  4. 9.4 Cholesterol Lowering Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst